Multicenter, single arm, phase II trial on the efficacy of ortataxel in recurrent glioblastoma

ConclusionOverall ortataxel treatment fail to demonstrate a significant activity in recurrent GBM patients. However in a limited number of patients the drug produced a benefit that lasted for a long time.Trial registration: This study is registered with ClinicalTrials.gov, number NCT01989884.

Source: Journal of Neuro-Oncology - February 6, 2019 Category: Cancer & Oncology Source Type: research